#London #United Kingdom #Cancer Research #Leveraged Finance #Melanoma Research Alliance

Leveraged Finance Strikes a Milestone in Melanoma Research

On January 29, 2026, the British Museum became the backdrop for an inspiring philanthropic effort as over 700 leaders from the leveraged finance and private equity sectors convened for the second annual Leveraged Finance Fights Melanoma (LFFM). The event achieved a remarkable feat by raising a record £1.6 million to support groundbreaking melanoma research, endorsing the relentless dedication of the global capital markets community to combating this perilous disease.

With contributions from 90 various sponsoring firms, the financial support generated will enhance the Melanoma Research Alliance (MRA)’s initiatives, directing crucial investments into UK-based scientists focusing on innovative strategies for melanoma prevention, early detection, and effective treatment. This comprehensive approach aims not only to facilitate advancements in research but also to accelerate meaningful patient outcomes.

Prominent figures in the finance sector co-chaired the event, including Roxana Mirica from Apax Partners, Valeria Mollova of Apollo, Leo Wouters of General Atlantic, and Sean Costello from Fitch Ratings, among others. Their leadership amplified the event’s impact, fostering an atmosphere of collaboration and resilience in the fight against melanoma.

The extensive host committee featured high-profile representatives from leading firms, displaying a united front in the struggle against cancer. Notable contributors included Peter Atkinson of HPS, Ian Barratt from Kirkland & Ellis, and Laura van Alkemade of Goldman Sachs, showcasing the depth of commitment among financial leaders towards meaningful social impact.

Stephanie Kauffman, president of the MRA, emphasized the significance of LFFM events by stating, “What makes LFFM so powerful is that it brings the discipline and ambition of the capital markets to one of the most urgent challenges in medicine.” The dramatic £1.6 million raised is earmarked for research endeavors led by outstanding scientists within the UK, targeting breakthroughs that could potentially save countless lives.

Founded in 2011 in New York by finance leaders Jeff Rowbottom from General Atlantic and Brandon Dillion from Veritas Capital, the Leveraged Finance Fights Melanoma initiative has unified professionals across leveraged finance, private equity, and credit markets in a focused mission to eliminate melanoma. Since its inception, LFFM events held in both New York and London have garnered over $35 million USD, proving the initiative’s global influence and effectiveness in funding vital melanoma research.

The history of the Melanoma Research Alliance stands out as a noteworthy aspect of this cause. Established in 2007 with the goal of advancing melanoma research, the MRA has emerged as the world's largest non-profit funder in this domain. With an impressive investment exceeding $175 million USD, the Alliance has propelled research that led to 17 FDA-approved therapies, influencing advances not only in melanoma but across various other cancers and diseases.

In a world where the urgency to combat cancer is paramount, the sustained efforts of the leveraged finance community signify a significant step forward. By fostering an environment where collaboration meets financial commitment, the fight against melanoma continues to gain momentum. Those interested in participating can look forward to future initiatives, continuing to shed light on this critical health issue while supporting scientists in their mission to affect real change.

For further details on leveraging finance for melanoma research or to explore partnership opportunities, visit Melanoma Research Alliance.